“Our mission is to create both strategic and financial returns by backing scalable technologies that can transform how biopharma operates.” Bill Taranto, president and general partner of the Merck Global Health Innovation Fund, joins Bloomberg Intelligence analyst Jonathan Palmer to break down how Merck’s $600 million evergreen venture arm invests at the intersection of biotech and health tech. Taranto explains why GHI focuses on pharma services across drug development, supply chain, patient access and real-world evidence, how ecosystem investing and private equity drive scale, and why AI and data are reshaping the future of pharma operations.

&ldquo;Our mission is to create both strategic and financial returns by backing scalable technologies that can transform how biopharma operates.&rdquo; Bill Taranto, president and general partner of the Merck Global Health Innovation Fund, joins Bloomberg Intelligence analyst Jonathan Palmer to break down how Merck&rsquo;s $600 million evergreen venture arm invests at the intersection of biotech and health tech. Taranto explains why GHI focuses on pharma services across drug development, supply chain, patient access and real-world evidence, how ecosystem investing and private equity drive scale, and why AI and data are reshaping the future of pharma operations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

Vanguards of Health Care by Bloomberg Intelligence

Merck’s GHI Fund and the Push to Rewire Pharma's Future

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e33d651e-63ab-4303-b264-b3cc01027ca5/transcript

“We were a very valuable deep-science company that had the wrong business strategy,” Zymeworks CEO Ken Galbraith tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. In discussing the company’s strategic reset, Galbraith explains how Zymeworks shifted from a platform-heavy biotech to a partnership-driven model that balances innovation with capital discipline. The conversation covers zanidatamab’s path to market, lessons from partnering with Jazz and BeOne, the value of asymmetric antibody design and why retaining upside through milestones and royalties could reshape long-term value creation.

&ldquo;We were a very valuable deep-science company that had the wrong business strategy,&rdquo; Zymeworks CEO Ken Galbraith tells Bloomberg Intelligence analyst Sam Fazeli on this episode of the Vanguards of Health Care podcast. In discussing the company&rsquo;s strategic reset, Galbraith explains how Zymeworks shifted from a platform-heavy biotech to a partnership-driven model that balances innovation with capital discipline. The conversation covers zanidatamab&rsquo;s path to market, lessons from partnering with Jazz and BeOne, the value of asymmetric antibody design and why retaining upside through milestones and royalties could reshape long-term value creation.

Zymeworks on Rethinking Risk, Royalties and R&D

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d885d277-28bd-4245-bb4a-b3ca014f0dfc/transcript

Vanguards of Health Care: Penumbra Expands CAVT Awareness “With pulmonary embolism, just like with stroke and some other things, where there’s an acute moment usually happening — the patient’s not doing well, decompressing on the table — time matters a lot. And because of the STORM-PE trial, we have the data on what that device time is in a pretty rigorous randomized study. And it just doesn’t compare to anything else out there. It’s dramatically less”, Penumbra CEO Adam Elsesser explains to Bloomberg Intelligence.


In this Vanguards of Health Care episode, Elsesser sits down with BI medical technology analyst Matt Henriksson for an in-depth interview on Penumbra and how computer-assisted vacuum thrombectomy (CAVT) technology continues to improve, cutting the time to remove the clot while limiting blood loss. He also dives deep into the clinical results of the STORM-PE randomized clinical study, highlighting how CAVT demonstrated superiority over the standard of care to treat pulmonary-embolism patients, and its partnership with the PERT Consortium to drive public awareness of the need to treat this devastating disease.

Vanguards of Health Care: Penumbra Expands CAVT Awareness &ldquo;With pulmonary embolism, just like with stroke and some other things, where there&rsquo;s an acute moment usually happening &mdash; the patient&rsquo;s not doing well, decompressing on the table &mdash; time matters a lot. And because of the STORM-PE trial, we have the data on what that device time is in a pretty rigorous randomized study. And it just doesn&rsquo;t compare to anything else out there. It&rsquo;s dramatically less&rdquo;, Penumbra CEO Adam Elsesser explains to Bloomberg Intelligence.
 In this Vanguards of Health Care episode, Elsesser sits down with BI medical technology analyst Matt Henriksson for an in-depth interview on Penumbra and how computer-assisted vacuum thrombectomy (CAVT) technology continues to improve, cutting the time to remove the clot while limiting blood loss. He also dives deep into the clinical results of the STORM-PE randomized clinical study, highlighting how CAVT demonstrated superiority over the standard of care to treat pulmonary-embolism patients, and its partnership with the PERT Consortium to drive public awareness of the need to treat this devastating disease.

Penumbra Builds Clinical Support Showing Computer Assistance Can Better Address Clot

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d9c7abb2-8d75-424a-b5a2-b3b6013396f0/transcript

“Drug development has become slower and more expensive despite all the new technology,” says Eric Hughes, executive vice president of Global R&D and chief medical officer of Teva Pharmaceutical. “That’s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we’re in a unique position where we can stay really hyper-focused on what we’re doing. I’m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they’re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva’s doing right.” In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.

&ldquo;Drug development has become slower and more expensive despite all the new technology,&rdquo; says Eric Hughes, executive vice president of Global R&amp;D and chief medical officer of Teva Pharmaceutical. &ldquo;That&rsquo;s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we&rsquo;re in a unique position where we can stay really hyper-focused on what we&rsquo;re doing. I&rsquo;m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they&rsquo;re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva&rsquo;s doing right.&rdquo; In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&amp;D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.

Teva a Generic Giant With Biotech Bite

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/c2b717d6-2e03-48ae-871b-b3b100c8e6b4/transcript

Merck’s GHI Fund and the Push to Rewire Pharma's Future

In 1 playlist(s)

Vanguards of Health Care by Bloomberg Intelligence

Social links

Follow podcast

Recent clips